Pfizer Ltd (PFIZER)
₹3,687.80
Mkt cap
₹16,871 Cr
P/E ratio
21.90
P/B
4.01
Div yield
2.03%
ROE
18.00%
ROCE
24.10%
EPS (TTM)
₹168.39
Book value
₹919
52W range
3,589–5,357
Sector
Healthcare
Price history
Previous close
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]
NSE PFIZERBSE 500680
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−31.16% from high₹3,688
₹3,589+2.75% from low₹5,357
Current
₹3,687.80
Prev close
₹3,759.80
Day
−1.91%
Price performance
1D
−1.83%
1W
+2.18%
1M
−5.67%
3M
−23.12%
6M
−22.51%
1Y
−30.33%
YTD
−24.54%
Financials
Revenue, profit & margin
P/E ratio
21.9×
PFIZER is 36% below the sector median of 34.4×
PFIZER21.9×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | |
| Expenses | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 | |
| Operating Profit | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 | |
| OPM % | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% | 38% | |
| Other Income | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 | 45 | |
| Interest | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | |
| Depreciation | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 | |
| Profit before tax | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 | |
| Tax % | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% | |
| Net Profit | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 | |
| EPS in Rs | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 | 44.70 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.06% · closed higher next day 19 of last 55
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 9 Feb '24◦ | 17 May '24◦ | 29 Jul '24◦ | 28 Oct '24◦ | 31 Jan '25◦ | 20 May '25◦ | 13 Aug '25◦ | 12 Nov '25◦ | 9 Feb '26◦ | 12 May '26◦ | 28 Jul '26 |
| Earnings day | +0.19% | −0.00% | +1.65% | +3.99% | −1.37% | +0.54% | +0.59% | +4.33% | +0.56% | +4.13% | −2.38% | +0.94% |
| +1 day | −0.05% | −0.73% | −0.41% | +5.27% | −3.25% | −0.75% | +3.83% | +12.91% | +1.17% | +9.10% | −0.95% | +1.92% |
| +5 days | −0.61% | +5.61% | +3.43% | +7.92% | +0.96% | −3.97% | +11.34% | +10.99% | +0.26% | +6.06% | −0.81% | +4.19% |
| +15 days | +2.53% | +5.30% | +11.99% | +11.32% | −0.81% | −9.76% | +16.69% | +0.71% | −0.29% | +2.15% | −6.42% | +4.43% |
| +30 days | +4.09% | −3.59% | +4.08% | +14.01% | −4.64% | −10.18% | +15.46% | −3.95% | +0.73% | −1.15% | −5.61% | −11.46% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 75 Per Share | 75.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
as of Sep 202663.92%Promoter
Promoters63.92%
FIIs1.63%0.02
DIIs17.52%0.28
Public16.93%0.31
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Pfizer | ₹3,687.80 | 21.94 | 16,871 | 2.03% | 204 | +6.63% | 653 | +8.31% | 24.06% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts7
Announcements5
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026. 26 Oct - Board meets November 3, 2026 to approve Q2 and half-year FY2026 unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Pfizer submitted Regulation 74(5) compliance certificate for quarter ended September 30, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Oct - Copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.Closure of Trading Window 29 Sep - Trading window closed from September 30, 2026 until 48 hours after half-year results.Intimation Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015. 29 Sep - Pfizer received Rs 1.26 crore transfer pricing penalty for AY2023-24 and will appeal.